LUPIN Share Price Target 2024 :- Lupin, a global pharmaceutical giant based in Mumbai, Maharashtra, is well-known for its focus on key therapeutic areas such as pediatrics, anti-infectives, cardiovascular, asthma, diabetology, and anti-tuberculosis treatments. The company’s stock performance has been impressive recently, with a notable price-to-earnings (PE) ratio of 50. Over the past month, Lupin’s shares have surged by 12.79%, and over the last six months, they have gained a remarkable 59.79%.
In this analysis, we’ll delve into whether it’s a wise decision to buy, hold, or sell Lupin shares at this juncture, considering its recent performance, valuation, and industry outlook.
LUPIN Share Price Target 2024
Lupin’s strong performance in the stock market reflects both investor confidence and the company’s strategic positioning in high-demand therapeutic areas. The pharmaceutical industry has been resilient, with a growing need for chronic disease management and infectious disease treatments. Lupin’s expertise in these areas, particularly in anti-infectives and cardiovascular drugs, positions it well for sustained growth.
However, a PE ratio of 50 suggests that the stock is currently trading at a high valuation, potentially pricing in future growth expectations. Investors should consider whether this optimism is justified based on the company’s financial health, pipeline of new drugs, and competitive positioning. Additionally, the broader market conditions, regulatory environment, and potential risks associated with the pharmaceutical sector must be weighed.
In the following analysis, we will explore these factors in detail to determine if Lupin’s current valuation offers a good buying opportunity, or if it might be prudent to hold or even sell shares, locking in recent gains.
Lupin Company Profile
| Aspect | Details |
|---|---|
| Company Name | Lupin Limited |
| Headquarters | Mumbai, Maharashtra, India |
| Industry | Pharmaceuticals |
| Founded | 1968 |
| Founder | Dr. Desh Bandhu Gupta |
| Key Focus Areas | Pediatrics, Anti-Infectives, Cardiovascular, Asthma, Diabetology, Anti-Tuberculosis |
| Global Presence | Over 100 countries, including the U.S., Europe, and Japan |
| Market Capitalization | Approximately INR 53,000 crore (as of recent estimates) |
| PE Ratio | 50 |
| Recent Stock Performance | +12.79% in the last month, +59.79% in the last six months |
| Core Products | Generic Pharmaceuticals, Active Pharmaceutical Ingredients (APIs), Biotechnology Products |
| Key Markets | United States, India, Europe, Japan, South Africa |
| R&D Centers | India, United States, Europe |
| Revenue | INR 16,369 crore (FY 2022-23) |
| Number of Employees | Over 20,000 |
| Notable Achievements | Among the top 10 generic pharmaceutical companies globally |
| Website | www.lupin.com |
Lupin Fundamentals
| Metric | Details |
|---|---|
| Market Capitalization | Approximately INR 53,000 crore (as of recent estimates) |
| Revenue (FY 2022-23) | INR 16,369 crore |
| Net Profit (FY 2022-23) | INR 605 crore |
| Earnings Per Share (EPS) | INR 13.31 |
| Price to Earnings (PE) Ratio | 50 |
| Dividend Yield | 0.5% |
| Debt to Equity Ratio | 0.28 |
| Return on Equity (ROE) | 5.6% |
| Return on Assets (ROA) | 3.2% |
| Operating Margin | 12.5% |
| Net Profit Margin | 3.7% |
| Current Ratio | 1.78 |
| Book Value per Share | INR 236.5 |
| Free Cash Flow (FY 2022-23) | INR 1,350 crore |
| Debt | INR 5,200 crore |
| Interest Coverage Ratio | 3.5 |
| Stock Beta | 0.85 (indicating lower volatility compared to market) |
Lupin Historical Chart
LUPIN Share Price Target 2024
| Month | Target Price(approx.) |
| August 2024 target | ₹2010 |
| September 2024 target | ₹2123 |
| October 2024 target | ₹2224 |
| November 2024 target | ₹2295 |
| December 2024 target | ₹2526 |
LUPIN Share Price Target 2025
| Month | Target Price(approx.) |
| January 2025 target | ₹2883 |
| February 2025 target | ₹2941 |
| March 2025 target | ₹3000 |
| April 2025 target | ₹2900 |
| May 2025 target | ₹2803 |
| June 2025 target | ₹2710 |
| July 2025 target | ₹2818 |
| August 2025 target | ₹2931 |
| September 2025 target | ₹3048 |
| October 2025 target | ₹3109 |
| November 2025 target | ₹3171 |
| December 2025 target | ₹3234 |
More Read
- Yes Bank Share Price Target
- Top 10 New Companies to Invest in the Stock Market
- PNB Share Price Target
- Best Company In Stock Market
LUPIN Share Price Target 2026
| Month | Target Price (approx.) |
| January 2026 target | ₹3299 |
| February 2026 target | ₹3365 |
| March 2026 target | ₹3432 |
| April 2026 target | ₹3318 |
| May 2026 target | ₹3208 |
| June 2026 target | ₹3101 |
| July 2026 target | ₹3225 |
| August 2026 target | ₹3354 |
| September 2026 target | ₹3488 |
| October 2026 target | ₹3558 |
| November 2026 target | ₹3629 |
| December 2026 | ₹3702 |
LUPIN Share Price Target 2027
| Month | Target Price (approx.) |
| January 2027 target | ₹3776 |
| February 2027 target | ₹3852 |
| March 2027 target | ₹3929 |
| April 2027 target | ₹3798 |
| May 2027 target | ₹3672 |
| June 2027 target | ₹3550 |
| July 2027 target | ₹3692 |
| August 2027 target | ₹3840 |
| September 2027 target | ₹3994 |
| October 2027 target | ₹4074 |
| November 2027 target | ₹4155 |
| December 2027 target | ₹4238 |
LUPIN Share Price Target 2028 to 2030
| Month | Target Price (approx.) |
| 2028 target | ₹4402 |
| 2029 target | ₹4654 |
| 2030 target | ₹4754 |
Federal Bank Shareholding Pattern
| Category | Percentage of Holding (%) |
|---|---|
| Promoters & Promoter Group | 46.96% |
| Foreign Institutional Investors (FIIs) | 19.50% |
| Domestic Institutional Investors (DIIs) | 18.33% |
| Public Shareholding | 14.88% |
| Others | 0.33% |
Lupin Ltd Competitors
| Competitor | Headquarters | Key Focus Areas |
|---|---|---|
| Sun Pharmaceutical | Mumbai, Maharashtra, India | Generic Drugs, Specialty Medicines, APIs |
| Dr. Reddy’s Laboratories | Hyderabad, Telangana, India | Generic Drugs, APIs, Biosimilars |
| Cipla | Mumbai, Maharashtra, India | Respiratory, Oncology, Antiretrovirals |
| Aurobindo Pharma | Hyderabad, Telangana, India | Generic Drugs, Injectables, Biosimilars |
| Torrent Pharmaceuticals | Ahmedabad, Gujarat, India | Cardiovascular, Central Nervous System, Diabetology |
| Glenmark Pharmaceuticals | Mumbai, Maharashtra, India | Dermatology, Respiratory, Oncology |
| Zydus Lifesciences | Ahmedabad, Gujarat, India | Generics, Vaccines, Biologics, Animal Health |
| Biocon | Bangalore, Karnataka, India | Biosimilars, Novel Biologics, Generic Formulations |
Points to consider before investing in lupin Stock
1. Valuation
- PE Ratio: Lupin is trading at a PE ratio of 50, which is relatively high compared to industry peers. Assess whether the current valuation is supported by expected future earnings growth.
2. Recent Stock Performance
- Price Movement: The stock has risen 12.79% in the last month and 59.79% over the last six months. Consider whether this uptrend is sustainable or if the stock might be overbought.
3. Industry Position
- Therapeutic Focus: Lupin is a major player in key therapeutic areas such as cardiovascular, anti-infectives, and anti-tuberculosis. Evaluate its competitive edge and the strength of its product pipeline in these high-demand areas.
4. Financial Health
- Debt Levels: Lupin’s debt-to-equity ratio and interest coverage ratio should be reviewed to ensure the company is not overly leveraged, which could limit its financial flexibility.
- Profit Margins: Check the company’s operating and net profit margins to understand its efficiency and profitability.
5. Regulatory Environment
- Compliance Risks: The pharmaceutical industry is subject to stringent regulations. Consider the potential impact of regulatory changes or compliance issues, particularly in key markets like the U.S. and Europe.
6. Research and Development
- Innovation Pipeline: Lupin’s success relies heavily on its R&D capabilities. Evaluate the company’s investment in R&D and its pipeline of new drugs, which are critical for long-term growth.
7. Market Risks
- Global Operations: With a presence in over 100 countries, Lupin is exposed to geopolitical risks, currency fluctuations, and differing regulatory standards. Assess how these factors might impact its operations and profitability.
8. Dividend Yield
- Income Generation: Lupin offers a relatively low dividend yield of around 0.5%. If you are seeking regular income, consider whether the potential capital appreciation outweighs the low dividend returns.
9. Competitive Landscape
- Rivalry: Lupin faces competition from other major pharmaceutical companies like Sun Pharma, Dr. Reddy’s, and Cipla. Analyze how Lupin’s strategies compare to its competitors in terms of market share and innovation.
10. Economic and Market Conditions
- Macroeconomic Factors: Consider the broader economic environment, including interest rates, inflation, and healthcare spending trends, which can affect Lupin’s business and stock performance.
Lupin Stock FAQs
Q1. What is Lupin’s PE ratio?
- Lupin’s PE ratio is currently 50.
Q2. What are Lupin’s recent stock performance metrics?
- The stock has increased by 12.79% in the last month and 59.79% in the last six months.
Q3. What are Lupin’s main therapeutic focus areas?
- Lupin focuses on pediatrics, anti-infectives, cardiovascular, asthma, diabetology, and anti-tuberculosis.
Q4 Does Lupin pay dividends?
- Yes, but the dividend yield is relatively low at around 0.5%.
Q5 What risks are associated with investing in Lupin?
- Risks include high valuation, regulatory hurdles, intense competition, and exposure to global market fluctuations.
Q6 How is Lupin’s debt situation?
- Lupin’s debt levels are manageable, but it’s important to review its debt-to-equity ratio and interest coverage.
Q7 What should investors consider about Lupin’s global operations?
- Lupin operates in over 100 countries, which introduces geopolitical, currency, and regulatory risks.
About Lupin Ltd
Lupin Ltd is a prominent global pharmaceutical company established in 1968 and headquartered in Mumbai, India. The company operates across several segments, including branded and generic formulations, biotechnology, active pharmaceutical ingredients (APIs), and animal health products.
Lupin’s portfolio features a range of prescription and over-the-counter medications, with best-sellers in antibiotics, cardiovascular drugs, antidiabetics, and anti-asthmatics. Notable branded products include Metoject, Lupitac, and Lupizole. Additionally, Lupin manufactures several well-known generic medications such as Amlodipine, Montelukast, and Cetirizine.
If you have invested in Lupine Share Price Target 2024, 2025, 2026, or would like to invest in it in the future, we have provided you with all the information you need to make that decision. Because we have conducted a fundamental to technical analysis in this post and provided you with information about the next activities, it may therefore prove to be very significant for you.